title: [Brain metastases from breast cancer: prognostic factors and tailored management].
abstract: During the last decades, advances in diagnostic and therapeutic technologies have modified the management of brain metastases, which is currently tailored to the type of primary site and to prognostic factors isolated in multivariate analyses. The aim of this article is to take stock of the current state of knowledge regarding prognostic factors in the setting of brain metastases from breast cancer as well as prognostic classifications proposed in this context. An appropriate multidisciplinary treatment for each prognostic class will be then discussed in light of the results of major randomized controlled trials enrolling patients with brain metastases from breast cancer.
authors: Institut Paoli-Calmettes, département d'oncologie-radiothérapie, 232, boulevard Sainte-Marguerite, 13273 Marseille cedex 09, France. talleta@marseille.fnclcc.fr
authors: Agnès
authors: A
authors: Tallet
authors: Youlia
authors: Y
authors: Kirova
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000473:pathology*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011379:Prognosis; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D003606:Dacarbazine; D000077204:Temozolomide